1. Introduction
inflammation, atopic skin diseases, eczema, psoriasis
ROSACEA, METABOLIC DISORDER, INFLAMMATION, PSORIASIS, PALMOPLANTAR KERATODERMA, SKIN CONDITION, SKIN DISORDERS, ECZEMA
We examined the effect of a dietary seaweed extract—sulfated xylorhamnoglucuronan (SXRG84)—on individuals with inflammatory skin conditions. A subgroup analysis of a larger trial was undertaken, where 44 participants with skin conditions were enrolled in a double-blind placebo-controlled crossover design. Subjects ingested either SXRG84 extract (2 g/day) for six weeks and placebo for six weeks, or vice versa. At baseline, six- and twelve-weeks inflammatory markers and the gut microbiota were assessed, as well as skin assessments using the dermatology quality of life index (DQLI), psoriasis area severity index (PASI) and visual analogue scales (VAS). There were significant differences at weeks six and twelve for pro-inflammatory cytokines IFN-γ (Microbiomes of both the skin and the gut are altered in skin disorders. Dietary modulation of systemic inflammation via the gut microbiome may be an effective tool in the management of atopic skin diseases [Several skin conditions have been associated with a dysbiosis of the gut microbiota, such as psoriasis, eczema and rosacea [Sulfated xylorhamnoglucuronan rich extract (SXRG84) from Ulva sp. is a novel prebiotic seaweed extract with the potential to attenuate some of the symptoms of metabolic disorder, as described in our previous, larger study [The aim of this study was to investigate the effect of SXRG84 administration on symptoms of inflammatory skin conditions in a randomised, double-blind, placebo-controlled trial. It was hypothesised that improvements in inflammatory skin conditions would be observed after the ingestion of the novel seaweed extract SXRG84.Furthermore, two case studies of skin conditions (Palmoplantar Keratoderma (PPK) [